EMERGENT BIOSOLUTIONS INC. Assets, Fair Value Disclosure
EMERGENT BIOSOLUTIONS INC. (EBS) had Assets, Fair Value Disclosure of $50.10 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Fair Value, Net Asset (Liability)
us-gaap:AssetsFairValueDisclosure · last filed 2026-08-06
- 2026-06-30: Assets, Fair Value Disclosure $50.10M.
- 2026-03-31: Assets, Fair Value Disclosure $81.80M.
- 2025-12-31: Assets, Fair Value Disclosure $162.00M.
- 2025-09-30: Assets, Fair Value Disclosure $105.80M.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $50.10M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $81.80M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $162.00M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $105.80M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $148.90M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $94.30M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $45.70M 10-K · filed 2026-02-27 |
| 2024-09-30 | $75.40M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $10.90M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $10.70M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $40.50M 10-K · filed 2025-03-04 |
| 2023-09-30 | $37.20M 10-Q · filed 2023-12-11 |
| 2023-06-30 | $20.10M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $308.30M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $500.00M 10-K · filed 2024-03-08 |
| 2022-09-30 | $75.70M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $181.60M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $260.10M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $352.40M 10-K/A · filed 2023-12-11 |
| 2021-09-30 | $232.40M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $322.50M 10-Q · filed 2021-07-30 |
| 2021-03-31 | $450.10M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $352.20M 10-K · filed 2022-02-25 |
| 2013-09-30 | $32.72M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $36.32M 10-Q · filed 2013-08-06 |
| 2012-12-31 | $42.72M 10-Q · filed 2013-11-08 |
| 2012-09-30 | $62.90M 10-Q · filed 2012-11-01 |
| 2011-12-31 | $74.97M 10-Q · filed 2012-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |